Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Taysha Gene Therapies (TSHA) Receivables - Other (2022 - 2025)

Taysha Gene Therapies' Receivables - Other history spans 4 years, with the latest figure at $2.6 million for Q3 2025.

  • For Q3 2025, Receivables - Other changed 0.0% year-over-year to $2.6 million; the TTM value through Sep 2025 reached $2.6 million, changed 0.0%, while the annual FY2024 figure was $2.6 million, 0.0% changed from the prior year.
  • Receivables - Other for Q3 2025 was $2.6 million at Taysha Gene Therapies, roughly flat from $2.6 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $2.6 million in Q1 2022 and bottomed at $2.6 million in Q1 2022.
  • The 4-year median for Receivables - Other is $2.6 million (2022), against an average of $2.6 million.
  • The largest YoY upside for Receivables - Other was 0.0% in 2023 against a maximum downside of 0.0% in 2023.
  • A 4-year view of Receivables - Other shows it stood at $2.6 million in 2022, then changed by 0.0% to $2.6 million in 2023, then changed by 0.0% to $2.6 million in 2024, then changed by 0.0% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Receivables - Other are $2.6 million (Q3 2025), $2.6 million (Q2 2025), and $2.6 million (Q1 2025).